Roche returns to Hansoh with broad $15B ADC deal
PartnershipPositive
AI Analysis
Summary
Roche is partnering with Hansoh Pharmaceutical in a deal with $400 million upfront and over $15 billion in potential milestone payments to develop a portfolio of new antibody-drug conjugates using Hansoh's proprietary technology. The article describes this as a return to Hansoh for Roche.
Outcome Details
Roche to pay $400 million upfront and over $15 billion in biobucks to collaborate with Hansoh on developing a portfolio of new antibody-drug conjugates using Hansoh's in-house technology.
Importance:8/10
Sentiment:
0.70
ADCantibody-drug conjugatelicensingpartnershiponcologyChinabiobucksupfront payment
Read the original article
Published by BioSpace on October 19, 2026 2:30 PM